Ocular surface toxicity of depatuxizumab mafoditin (ABT-414): case reports

Carlos Rocha-de-Lossada; Carmen Alba Linero; Álvaro Santos Ortega; Marina Rodríguez Calvo-de-Mora; Rahul Rachwani; Davide Borroni; Emilio Alba; Manuel Benavides Orgaz; Vito Romano

Ocular surface toxicity of depatuxizumab mafoditin (ABT-414): case reports

Carlos Rocha-de-Lossada, Carmen Alba Linero (Coresponding Author), Álvaro Santos Ortega, Marina Rodríguez Calvo-de-Mora, Rahul Rachwani, Davide Borroni, Emilio Alba, Manuel Benavides Orgaz, Vito Romano

Research output: Contribution to journal › Letter › peer-review

2 Downloads (Pure)

Abstract

The purpose of this study is to report the clinical features and outcomes of ocular surface toxicity following depatuxizumab mafoditin (ABT-414) therapy for unresectable glioblastoma. Ocular signs and symptoms of three patients treated with ABT-414 during a phase III trial for glioblastoma multiforme were evaluated. Both eyes of all patients were damaged during the week after the first infusion of the ABT-414 molecule. In all patients, mild-to-moderate keratitis could be ascertained, along with decreased visual acuity and blurred vision, as well as foreign-body sensation and redness. Symptoms and visual acuity improved 4 weeks. In conclusion, ABT-414 therapy may cause transient ocular surface toxicity. The initiation of artificial tears and lubricant ointment was enough to control the ocular surface signs and symptoms. A multidisciplinary approach, complete ophthalmologic monitorization, and elaboration of protocols are required to adequately manage these patients.

Original language	English
Pages (from-to)	411-414
Journal	Arquivos Brasileiros de Oftalmologia
Volume	85
Issue number	4
Publication status	Published - 2021

Field of Science*

3.2 Clinical medicine

Publication Type*

1.1. Scientific article indexed in Web of Science and/or Scopus database

Access to Document

Ocular surface toxicity of depatuxizumabeOther version, 242 KBLicence: CC BY

Cite this

@article{1ea40036bcb544f48134263a329a1964,

title = "Ocular surface toxicity of depatuxizumab mafoditin (ABT-414): case reports",

abstract = "The purpose of this study is to report the clinical features and outcomes of ocular surface toxicity following depatuxizumab mafoditin (ABT-414) therapy for unresectable glioblastoma. Ocular signs and symptoms of three patients treated with ABT-414 during a phase III trial for glioblastoma multiforme were evaluated. Both eyes of all patients were damaged during the week after the first infusion of the ABT-414 molecule. In all patients, mild-to-moderate keratitis could be ascertained, along with decreased visual acuity and blurred vision, as well as foreign-body sensation and redness. Symptoms and visual acuity improved 4 weeks. In conclusion, ABT-414 therapy may cause transient ocular surface toxicity. The initiation of artificial tears and lubricant ointment was enough to control the ocular surface signs and symptoms. A multidisciplinary approach, complete ophthalmologic monitorization, and elaboration of protocols are required to adequately manage these patients.",

author = "Carlos Rocha-de-Lossada and Linero, {Carmen Alba} and Ortega, {{\'A}lvaro Santos} and Calvo-de-Mora, {Marina Rodr{\'i}guez} and Rahul Rachwani and Davide Borroni and Emilio Alba and Orgaz, {Manuel Benavides} and Vito Romano",

year = "2021",

language = "English",

volume = "85",

pages = "411--414",

journal = "Arquivos Brasileiros de Oftalmologia",

issn = "0004-2749",

publisher = "Conselho Brasileiro De Oftalmologia",

number = "4",

}

TY - JOUR

T1 - Ocular surface toxicity of depatuxizumab mafoditin (ABT-414)

T2 - case reports

AU - Rocha-de-Lossada, Carlos

AU - Linero, Carmen Alba

AU - Ortega, Álvaro Santos

AU - Calvo-de-Mora, Marina Rodríguez

AU - Rachwani, Rahul

AU - Borroni, Davide

AU - Alba, Emilio

AU - Orgaz, Manuel Benavides

AU - Romano, Vito

PY - 2021

Y1 - 2021

N2 - The purpose of this study is to report the clinical features and outcomes of ocular surface toxicity following depatuxizumab mafoditin (ABT-414) therapy for unresectable glioblastoma. Ocular signs and symptoms of three patients treated with ABT-414 during a phase III trial for glioblastoma multiforme were evaluated. Both eyes of all patients were damaged during the week after the first infusion of the ABT-414 molecule. In all patients, mild-to-moderate keratitis could be ascertained, along with decreased visual acuity and blurred vision, as well as foreign-body sensation and redness. Symptoms and visual acuity improved 4 weeks. In conclusion, ABT-414 therapy may cause transient ocular surface toxicity. The initiation of artificial tears and lubricant ointment was enough to control the ocular surface signs and symptoms. A multidisciplinary approach, complete ophthalmologic monitorization, and elaboration of protocols are required to adequately manage these patients.

AB - The purpose of this study is to report the clinical features and outcomes of ocular surface toxicity following depatuxizumab mafoditin (ABT-414) therapy for unresectable glioblastoma. Ocular signs and symptoms of three patients treated with ABT-414 during a phase III trial for glioblastoma multiforme were evaluated. Both eyes of all patients were damaged during the week after the first infusion of the ABT-414 molecule. In all patients, mild-to-moderate keratitis could be ascertained, along with decreased visual acuity and blurred vision, as well as foreign-body sensation and redness. Symptoms and visual acuity improved 4 weeks. In conclusion, ABT-414 therapy may cause transient ocular surface toxicity. The initiation of artificial tears and lubricant ointment was enough to control the ocular surface signs and symptoms. A multidisciplinary approach, complete ophthalmologic monitorization, and elaboration of protocols are required to adequately manage these patients.

UR - https://www-webofscience-com.db.rsu.lv/wos/alldb/full-record/MEDLINE:34586240

M3 - Letter

C2 - 34586240

SN - 0004-2749

VL - 85

SP - 411

EP - 414

JO - Arquivos Brasileiros de Oftalmologia

JF - Arquivos Brasileiros de Oftalmologia

IS - 4

ER -

Ocular surface toxicity of depatuxizumab mafoditin (ABT-414): case reports

Abstract

Field of Science*

Publication Type*

Access to Document

Other files and links

Fingerprint

Cite this